Castle Biosciences (CSTL) Other Accumulated Expenses (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Other Accumulated Expenses data on file, last reported at $10.7 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 27.75% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (up 27.75% YoY) and the FY2025 annual result came in at $8.9 million, up 11.81% from the prior year.
• Other Accumulated Expenses climbed to $10.7 million in Q1 2026 per CSTL's latest filing, from $8.9 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $10.7 million in Q1 2026, with the low at $5.1 million in Q3 2022.
• Average Other Accumulated Expenses over 5 years is $7.4 million, with a median of $7.4 million recorded in 2024.
• Year-over-year, Other Accumulated Expenses soared 223.84% in 2022 and slipped 10.51% in 2023.
• Castle Biosciences' Other Accumulated Expenses stood at $5.3 million in 2022, then surged by 39.05% to $7.3 million in 2023, then rose by 9.24% to $8.0 million in 2024, then increased by 11.81% to $8.9 million in 2025, then climbed by 19.63% to $10.7 million in 2026.
• Business Quant data shows CSTL's Other Accumulated Expenses at $10.7 million in Q1 2026, $8.9 million in Q4 2025, and $8.9 million in Q3 2025.